Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited

Cost of Revenue Trends: Merck vs. Mesoblast

__timestamp	Merck & Co., Inc.	Mesoblast Limited
Wednesday, January 1, 2014	16768000000	25434000
Thursday, January 1, 2015	14934000000	23783000
Friday, January 1, 2016	13891000000	29763000
Sunday, January 1, 2017	12775000000	12065000
Monday, January 1, 2018	13509000000	5508000
Tuesday, January 1, 2019	14112000000	75173000
Wednesday, January 1, 2020	13618000000	81497000
Friday, January 1, 2021	13626000000	85731000
Saturday, January 1, 2022	17411000000	63572000
Sunday, January 1, 2023	16126000000	54922000
Monday, January 1, 2024		41070000

Unleashing insights

Analyzing Cost of Revenue: Merck & Co., Inc. vs. Mesoblast Limited

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. From 2014 to 2023, Merck & Co., Inc. and Mesoblast Limited have shown contrasting trends in their cost of revenue. Merck, a global pharmaceutical giant, experienced a 24% decrease in cost of revenue from 2014 to 2017, followed by a resurgence, peaking in 2022. This reflects strategic shifts and market adaptations. Meanwhile, Mesoblast, a smaller biotech firm, saw a dramatic 1,200% increase from 2014 to 2021, highlighting its aggressive growth and investment in R&D. However, 2023 data for Merck is missing, indicating potential reporting delays or strategic changes. These insights underscore the dynamic nature of the pharmaceutical industry, where cost management is as critical as innovation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025